Joel Geerling
@geerling-lab.bsky.social
Neuroanatomy - Cognitive & Behavioral Neurology - Iowa Neuroscience Institute
See also the accompanying bioRxiv paper on the Ten3/Lphn2 gradient in the developing hippocampus:
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Ten3–Lphn2-mediated target selection across the extended hippocampal network demonstrates a repeated strategy for circuit assembly
How do a limited number of wiring molecules specify trillions of connections in developing brains? We previously found that inverse expression of a ligand–receptor pair, Teneurin-3 (Ten3) and Latrophi...
www.biorxiv.org
August 15, 2025 at 5:20 PM
See also the accompanying bioRxiv paper on the Ten3/Lphn2 gradient in the developing hippocampus:
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
But Brawndo’s what plants crave! It’s got electrolytes!
February 8, 2025 at 10:36 PM
But Brawndo’s what plants crave! It’s got electrolytes!
What is the home test you referenced? (empowerdx maybe?)
January 5, 2025 at 10:21 PM
What is the home test you referenced? (empowerdx maybe?)
What lab runs your APOE tests? Is it in the USA, CLIA certified?
January 5, 2025 at 10:18 PM
What lab runs your APOE tests? Is it in the USA, CLIA certified?
70% by 80y (clinical-stage dementia symptoms) undersells the disease risk (see Fig 1 of www.nature.com/articles/s41...).
Lifetime penetrance of Alzheimer’s-type neuropathologic change is closer to 100% (www.nature.com/articles/s41...).
Lifetime penetrance of Alzheimer’s-type neuropathologic change is closer to 100% (www.nature.com/articles/s41...).
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study - Nature Communications
APOE is the major genetic risk factor for Alzheimer’s disease. In a large number of neuropathologically confirmed cases and controls, the impact of different APOE genotypes on Alzheimer’s dementia ris...
www.nature.com
January 5, 2025 at 10:03 PM
70% by 80y (clinical-stage dementia symptoms) undersells the disease risk (see Fig 1 of www.nature.com/articles/s41...).
Lifetime penetrance of Alzheimer’s-type neuropathologic change is closer to 100% (www.nature.com/articles/s41...).
Lifetime penetrance of Alzheimer’s-type neuropathologic change is closer to 100% (www.nature.com/articles/s41...).